Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.

ABSTRACT:

Background and rationale

Most patients with chronic hepatitis C show virological response to telaprevir-based triple therapy, and achieve an end-of-treatment response (ETR). However, some patients showing ETR develop virological relapse. This study was carried out to evaluate factors associated with relapse after triple therapy.

Materials and methods

A prospective, multicentric study was conducted in chronic hepatitis C patients who received telaprevir-based triple therapy. We evaluated independent variables such as age, with or without cirrhosis, prior treatment response to interferon (IFN) therapy, IL28B genotype, core amino acid (aa) 70 mutation, drug adherence, white blood cell counts, hemoglobin level, and serum low-density lipoprotein (LDL) cholesterol level. The chara

SUBMITTER: Kondo C 

PROVIDER: S-EPMC4944324 | biostudies-literature | 2016 Jan-Mar

REPOSITORIES: biostudies-literature